Search this Site

Amoxicillin News

Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial.

Background: For children at high risk of chronic suppurative otitis media (CSOM), strategies to prevent acute otitis media with perforation (AOMwiP) may reduce progression to CSOM.

Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.

The Brazilian consensus recommends a short-term treatment course with clarithromycin, amoxicillin and proton-pump inhibitor for the eradication of Helicobacter pylori (H. pylori).

Ampicillin plus Ceftriaxone for High-Level Aminoglycoside-Resistant Enterococcus faecalis Endocarditis

We read with interest the letter by Dr. Singh regarding our article. First, we would like to clarify that the cure rate for HLAR E. faecalis endocarditis was 71.4%, far greater than the best cure rate reached with a...

FDA Approves First Once-Daily Amoxicillin

Amoxicillin-makers watch out. MiddleBrook Pharmaceuticals has received FDA approval for Moxatag once-daily, extended-release, 775-mg tablets for treating pharyngitis or tonsillitis secondary to Streptococcus pyogenes — also known...

Feuerstein's Biotech-Stock Mailbag

Welcome back to the Biotech Mailbag. This week, I'll tackle questions on Middlebrook Pharmaceuticals and Isis Pharmaceuticals.

Displaying results 1 to 5 out of 41

1

2

3

4

5

6

7

Next >

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.